Eli Lilly is trading 3.4% down at $1,165.73 as managed care weakness drags the broader healthcare sector lower.
- The move occurs without fresh company-specific news, underperforming a broadly higher U.S. market.
- The stock has seen strong recent momentum in its obesity and diabetes franchise and raised 2026 profit guidance earlier this year.